Deborah Chirnomas

Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway

Deborah Chirnomas, Toshiyasu Taniguchi, Michelle de la Vega et al. · Molecular Cancer Therapeutics · 2006 · 206 citations

TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements

Hong-Yan Du, Elena Pumbo, Jennifer Ivanovich et al. · Blood · 2008 · 154 citations · Full text

Deferasirox pharmacokinetics in patients with adequate versus inadequate response

Deborah Chirnomas, Amber Lynn Smith, Jennifer Braunstein et al. · Blood · 2009 · 91 citations · Full text

Abstract PD13-08: First-in-human safety and activity of ARV-471, a novel PROTAC® estrogen receptor degrader, in ER+/HER2- locally advanced or metastatic breast cancer

Erika Hamilton, Linda T. Vahdat, Hyo S. Han et al. · Cancer Research · 2022 · 57 citations

First-in-human Safety, Breast Oncology, Estrogen Receptor +16

A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload

Hugh Young Rienhoff, Vip Viprakasit, Lay H. Tay et al. · Haematologica · 2010 · 40 citations · Full text